Seeking Alpha

After a post-earnings (I, II) meeting with management, Jefferies isn't too concerned about the...

After a post-earnings (I, II) meeting with management, Jefferies isn't too concerned about the recent Medicare/ Medicaid "setback" for Cyberonics' (CYBX +0.5%) VNS Therapy (previous). "The addressable market" could be expanded to include new indications like congestive heart failure analyst Raj Denhoy says, and besides, CYBX "is firing on all cylinders in epilepsy." Ultimately, "strong, sustainable growth" equals a reiterated Buy rating (PT $60).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|